Aziyo Biologics, Inc. (NASDAQ:AZYO) Q4 2022 Earnings Call Transcript

Randy Mills: Yes. Thanks, Josh. No, they are currently not selling an acellular dermal matrix. They have the sales force of approximately 55 reps, including a segment of those reps that actually specialize just in reconstruction or actually reconstruction experts. This is — reconstruction has become a priority for them. And for us, what this — this is really, for us, it’s like shooting SimpliDerm out of a cannon. We have a limited sales group now of our own that’s distributing it. But it opens up the geography for us in the United States really exponentially and does so in a way where the reps — these 55 reps that are carrying this product are in these cases every day where the product would be used. And so, we think it’s — for us, we think it could be a very, very significant acceleration of a product that’s already growing, like, something in the order of 40% year-over-year.

And so that’s saying quite a bit. We also think it’s a good partnership in terms of the product being as strategically important for Sientra as it is for Aziyo. So, we’re super excited about it.

Josh Jennings: That’s great to hear. Thanks again. Appreciate it.

Randy Mills: Thanks, Josh.

Operator: Thank you. And there are no further questions today. And with that, we conclude today’s conference. All parties may disconnect. Thank you all for your participation.